

June 4, 2020

The Manger - Listing

BSE Limited

Corporate Relationship Dept., 1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

National Stock Exchange of India Ltd.

Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Disclosure of Related Party Transactions

Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended March 31, 2020 for your information and records.

For AstraZeneca Pharma India limited


Pratap Rudra
Company Secretary & Legal Counsel



AstraZeneca Pharma India Limited

Disclosure of related party transactions for the half year ended 31 March, 2020

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

(All amounts in Rs.million)

(i) Names of related parties and related party relationship

(a) Related parties where control exists and/or where transactions have occurred:

Name of the entity	Name of relationship
Holding Company	AstraZeneca Pharmaceuticals AB, Sweden
Holding Company of AstraZeneca Pharmaceuticals AB, Sweden	AstraZeneca AB, Sweden
Holding Company of AstraZeneca AB, Sweden	AstraZeneca Treasury Limited, United Kingdom
Ultimate Holding Company	AstraZeneca Plc, United Kingdom
Fellow subsidiaries with whom the company had transactions during the year	AstraZeneca Singapore Pte Ltd, Singapore AstraZeneca Pharmaceuticals LP, USA AstraZeneca UK Limited, United Kingdom P.T. AstraZeneca Indonesia AstraZeneca Pty Ltd, Australia AstraZeneca SDN Bhd, Malaysia
Employees' Benefit Plans	AstraZeneca Pharma India Limited Employees Gratuity Fund Trust AstraZeneca Pharma India Limited Management Staff Provident Fund Trust AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust

b) Key Management Personnel

- Managing Director	Mr. Gagandeep Singh Bedi
- Director and Chief Financial Officer	Mr. Rajesh Marvaha
- Non-Executive Directors	Mr. Ian John Parish Ms. Weiying Sarah Wang

c) Independent Directors

Mr. Narayan K Seshadri
Ms. Revathy Ashok
Ms. Kimsuka Narasimhan

(ii) Details of the transactions with the related parties during the period 01 October 2019 to 31 March 2020 :

Purchase of raw materials and traded goods	
AstraZeneca UK Limited, United Kingdom	1,567.9
AstraZeneca AB, Sweden	147.4
Payment towards reimbursement of expenses	
AstraZeneca UK Limited, United Kingdom	2.4
AstraZeneca Pty Ltd, Australia	4.6
Payment towards employee stock compensation expense, net of withholding tax	
AstraZeneca UK Limited, United Kingdom	-



AstraZeneca Pharma India Limited

Disclosure of related party transactions for the half year ended 31 March, 2020

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

(All amounts in Rs.million)

Sale of services	
AstraZeneca AB, Sweden	118.1
Recovery of reimbursable expenses	
AstraZeneca UK Limited, United Kingdom	44.1
AstraZeneca AB, Sweden	60.1
P.T. AstraZeneca Indonesia	5.2
AstraZeneca Singapore Pte Ltd, Singapore	3.6
AstraZeneca Pharmaceuticals LP, USA	2.7
AstraZeneca SDN Bhd, Malaysia	3.9
Contribution to Trusts	
AstraZeneca Pharma India Limited Employees Gratuity Fund Trust	50.0
AstraZeneca Pharma India Limited Management Staff Provident Fund Trust	52.6
AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust	12.6
(iii) (a) Transactions with Key Management Personnel	
Salary and perquisites	
Short-term employee benefits	23.7
Long-term employee benefits	8.0
Post employment benefits	16.8
Employee share compensation expenses	2.3
	<u>50.8</u>
(iii) (b) Transactions with Independent Directors	
Sitting fees paid to independent directors	2.1



AstraZeneca Pharma India Limited

Disclosure of related party transactions for the half year ended 31 March, 2020

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

(All amounts in Rs.million)

(iv) Details of balances receivable from and payable to related parties as at 31, March 2020 are as follows:

Other current financial assets	97.3
AstraZeneca UK Limited, United Kingdom	29.1
AstraZeneca Pharmaceuticals LP, USA	2.7
AstraZeneca Singapore Pte Ltd, Singapore	1.7
P.T. AstraZeneca Indonesia	2.5
AstraZeneca SDN Bhd, Malaysia	1.2
AstraZeneca AB, Sweden	60.1
Trade receivables	45.0
AstraZeneca AB, Sweden	45.0
Trade payables	816.2
AstraZeneca UK Limited, United Kingdom	713.4
AstraZeneca AB, Sweden	96.2
AstraZeneca Pty Ltd, Australia	6.6

